Aptose Biosciences (APTO) News Today $2.54 +0.08 (+3.25%) (As of 12/29/2023 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAptose Biosciences Inc. (NASDAQ:APTO) Short Interest Updateamericanbankingnews.com - December 31 at 2:40 AMAptose Biosciences Stock (NASDAQ:APTO), Guidance and Forecastbenzinga.com - December 21 at 1:08 AMAptose Biosciences Inc APTOmorningstar.com - December 5 at 10:43 PMAptose Biosciences files to sell ordinary shares, warrantsmsn.com - December 4 at 10:00 AMAptose Biosciences, Inc.: Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Rolefinanznachrichten.de - December 1 at 7:47 AMAptose Biosciences Inc. (APTO) Q3 2023 Earnings Call Transcriptseekingalpha.com - November 12 at 7:59 PMAptose Biosciences Stock (NASDAQ:APTO) Earnings Dates and Earning Callsbenzinga.com - November 11 at 8:49 PMAptose Biosciences: Q3 Earnings Insightsbenzinga.com - November 10 at 11:13 PMPromising Financial Performance and Clinical Developments Bolster Aptose Biosciences’ Buy Rating: An Analysis by Joseph Pantginismarkets.businessinsider.com - November 10 at 11:13 PMAptose Biosciences GAAP EPS of -$1.76 beats by $0.22msn.com - November 9 at 8:40 PMOppenheimer Reaffirms Their Buy Rating on Aptose Biosciences (APTO)markets.businessinsider.com - November 1 at 5:32 AMPromising Trial Data and Expansion Plans Boost Confidence in Aptose Biosciences: An Analysis of John Newman’s Buy Ratingmarkets.businessinsider.com - November 1 at 5:32 AMAptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinibfinance.yahoo.com - October 30 at 10:18 AMAptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conferencefinance.yahoo.com - October 16 at 8:22 AMAptose Biosciences: Bottom 25 Performing Stocks Year-to-Date on TSX (APS)theglobeandmail.com - October 12 at 5:32 PMCompanies Like Aptose Biosciences (TSE:APS) Could Be Quite Riskyfinance.yahoo.com - September 8 at 3:54 PMHANMI FILES EARLY WARNING REPORT IN RESPECT OF APTOSE BIOSCIENCES INC.finance.yahoo.com - September 7 at 6:50 PMExpert Ratings for Aptose Biosciencesmarkets.businessinsider.com - September 7 at 6:50 PMShort Interest in Aptose Biosciences Inc. (NASDAQ:APTO) Declines By 12.8%marketbeat.com - August 29 at 4:03 AMAptose to Present at the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - August 24 at 10:00 AMClosing Bell: Aptose Biosciences Inc down on Tuesday (APS)theglobeandmail.com - August 23 at 6:59 PMAptose Biosciences (NASDAQ: APTO)fool.com - August 18 at 2:01 AMRBC Capital Maintains Outperform Rating for Aptose Biosciences: Here's What You Need To Knowmarkets.businessinsider.com - August 11 at 7:33 PMRoyal Bank of Canada Cuts Aptose Biosciences (NASDAQ:APTO) Price Target to $23.00marketbeat.com - August 11 at 2:23 PMAptose Biosciences Inc. (NASDAQ:APTO) Receives Consensus Rating of "Buy" from Analystsmarketbeat.com - August 11 at 10:49 AMAptose Biosciences GAAP EPS of -$2.27 misses by $0.34msn.com - August 11 at 3:19 AMAptose Biosciences (APTO) Price Target Increased by 1614.75% to 62.90msn.com - August 2 at 5:02 PMAptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023finance.yahoo.com - July 28 at 2:05 AMAPTO - Aptose Biosciences Inc.finance.yahoo.com - June 27 at 11:27 PMAptose Biosciences Meets Nasdaq Minimum Bid Price Compliancefinance.yahoo.com - June 26 at 6:09 PMAptose Shares Up 11% After Study Presentation, Analysts' Target Boostsmarketwatch.com - June 12 at 7:46 PMOppenheimer Maintains Outperform on Aptose Biosciences, Raises Price Target to $50benzinga.com - June 12 at 2:46 PMAptose Biosciences shares are trading higher after multiple firms raised their respective price targets.benzinga.com - June 12 at 2:46 PMJonesTrading Keeps Their Buy Rating on Aptose Biosciences (APTO)markets.businessinsider.com - June 10 at 8:43 PMAptose Biosciences updates on reverse stock splitmsn.com - June 5 at 10:04 AMAptose Biosciences, Inc.: Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholdersfinanznachrichten.de - May 24 at 1:37 PMCaspase 3 Market Business Overview and Growth Forecast by 2030marketwatch.com - May 17 at 7:16 AMClosing Bell: Aptose Biosciences Inc down on Friday (APS)theglobeandmail.com - May 13 at 12:50 AMAptose Biosciences GAAP EPS of -$0.15 misses by $0.03msn.com - May 9 at 3:33 PMAnalyst Expectations for Aptose Biosciences's Futuremarkets.businessinsider.com - May 9 at 3:33 PMH.C. Wainwright Sticks to Its Buy Rating for Aptose Biosciences (APTO)markets.businessinsider.com - May 9 at 10:33 AMDiffuse Large B Cell Lymphoma Drug Market Outlook by 2031marketwatch.com - April 28 at 8:15 AMClosing Bell: Aptose Biosciences Inc down on Monday (APS)theglobeandmail.com - April 25 at 9:52 AMAptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023finance.yahoo.com - April 24 at 9:19 AMClosing Bell: Aptose Biosciences Inc up on Tuesday (APS)theglobeandmail.com - April 19 at 10:25 AMAptose to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conferencebenzinga.com - April 12 at 6:06 PMAptose to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conferencefinance.yahoo.com - April 10 at 6:21 PMClosing Bell: Aptose Biosciences Inc down on Thursday (APS)theglobeandmail.com - April 8 at 1:13 AMDiffuse Large B Cell Lymphoma Drug Market Share By 2031marketwatch.com - March 28 at 10:38 AMCanaccord Genuity Maintains Buy Rating for Aptose Biosciences: Here's What You Need To Knowmarkets.businessinsider.com - March 27 at 1:27 PM Get Aptose Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter. Email Address APTO Media Mentions By Week APTO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APTO News Sentiment▼0.430.84▲Average Medical News Sentiment APTO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APTO Articles This Week▼31▲APTO Articles Average Week Get Aptose Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Surrozen News Today Acorda Therapeutics News Today Entera Bio News Today PHAXIAM Therapeutics News Today Elevation Oncology News Today PharmaCyte Biotech News Today Evaxion Biotech A/S News Today TradeUP Acquisition News Today Protara Therapeutics News Today Pluri News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:APTO) was last updated on 12/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.